Gilead Sciences (GILD) Tops Q2 EPS by 14c
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $125.97 -0.29%
Revenue Growth %: +4.4%
Financial Fact:
Income before provision for income taxes: 4.28B
Today's EPS Names:
CRMT, FOMI, FLES, More
Revenue Growth %: +4.4%
Financial Fact:
Income before provision for income taxes: 4.28B
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.87, $0.14 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.07 billion.
GUIDANCE:
Gilead Sciences sees FY2021 EPS of $6.90-$7.25, versus the consensus of $7.07. Gilead Sciences sees FY2021 revenue of $24.4-25 billion, versus the consensus of $24.64 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- GNI Group acquires Ayumi Pharmaceutical for ¥44.8 billion
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
